Phenotypic diversity of brain MRI patterns in mitochondrial aminoacyl-tRNA synthetase mutations.


Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
06 2021
Historique:
received: 23 11 2020
revised: 15 02 2021
accepted: 16 04 2021
pubmed: 12 5 2021
medline: 11 9 2021
entrez: 11 5 2021
Statut: ppublish

Résumé

Mitochondrial aminoacyl-tRNA synthetases-encoded by ARS2 genes-are evolutionarily conserved enzymes that catalyse the attachment of amino acids to their cognate tRNAs, ensuring the accuracy of the mitochondrial translation process. ARS2 gene mutations are associated with a wide range of clinical presentations affecting the CNS. Two senior neuroradiologists analysed brain MRI of 25 patients (age range: 3 d-25 yrs.; 11 males; 14 females) with biallelic pathogenic variants of 11 ARS2 genes in a retrospective study conducted between 2002 and 2019. Though several combinations of brain MRI anomalies were highly suggestive of specific aetiologies (DARS2, EARS2, AARS2 and RARS2 mutations), our study detected no MRI pattern common to all patients. Stroke-like lesions were associated with pathogenic SARS2 and FARS2 variants. We also report early onset cerebellar atrophy and calcifications in AARS2 mutations, early white matter involvement in RARS2 mutations, and absent involvement of thalami in EARS2 mutations. Finally, our findings show that normal brain MRI results do not exclude the presence of ARS2 mutations: 5 patients with normal MRI images were carriers of pathogenic IARS2, YARS2, and FARS2 variants. Our study extends the spectrum of brain MRI anomalies associated with pathogenic ARS2 variants and suggests ARS2 mutations are largely underdiagnosed.

Sections du résumé

BACKGROUND AND PURPOSE
Mitochondrial aminoacyl-tRNA synthetases-encoded by ARS2 genes-are evolutionarily conserved enzymes that catalyse the attachment of amino acids to their cognate tRNAs, ensuring the accuracy of the mitochondrial translation process. ARS2 gene mutations are associated with a wide range of clinical presentations affecting the CNS.
METHODS
Two senior neuroradiologists analysed brain MRI of 25 patients (age range: 3 d-25 yrs.; 11 males; 14 females) with biallelic pathogenic variants of 11 ARS2 genes in a retrospective study conducted between 2002 and 2019.
RESULTS
Though several combinations of brain MRI anomalies were highly suggestive of specific aetiologies (DARS2, EARS2, AARS2 and RARS2 mutations), our study detected no MRI pattern common to all patients. Stroke-like lesions were associated with pathogenic SARS2 and FARS2 variants. We also report early onset cerebellar atrophy and calcifications in AARS2 mutations, early white matter involvement in RARS2 mutations, and absent involvement of thalami in EARS2 mutations. Finally, our findings show that normal brain MRI results do not exclude the presence of ARS2 mutations: 5 patients with normal MRI images were carriers of pathogenic IARS2, YARS2, and FARS2 variants.
CONCLUSION
Our study extends the spectrum of brain MRI anomalies associated with pathogenic ARS2 variants and suggests ARS2 mutations are largely underdiagnosed.

Identifiants

pubmed: 33972171
pii: S1096-7192(21)00695-8
doi: 10.1016/j.ymgme.2021.04.004
pii:
doi:

Substances chimiques

Mitochondrial Proteins 0
Amino Acyl-tRNA Synthetases EC 6.1.1.-
Aspartate-tRNA Ligase EC 6.1.1.12
DARS2 protein, human EC 6.1.1.12
Arginine-tRNA Ligase EC 6.1.1.19
RARS2 protein, human EC 6.1.1.19
FARS2 protein, human EC 6.1.1.20
Phenylalanine-tRNA Ligase EC 6.1.1.20
AARS2 protein, human EC 6.1.1.7
Alanine-tRNA Ligase EC 6.1.1.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

222-229

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Charles-Joris Roux (CJ)

Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France. Electronic address: charles-joris.roux@aphp.fr.

Giulia Barcia (G)

Department of Genetics, Hospital Necker-Enfants Malades, Paris, France.

Manuel Schiff (M)

Institut Imagine, INSERM UMR 1163, Paris, France; Necker Hospital, APHP, Reference Center for Inborn Error of Metabolism, Pediatrics Department, University of Paris, Paris, France.

Marie Sissler (M)

Institut Européen de Chimie et Biologie, INSERM U1212, CNRS UMR 5320, University of Bordeaux, Pessac, France.

Raphaël Levy (R)

Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France.

Volodia Dangouloff-Ros (V)

Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France.

Isabelle Desguerre (I)

Department of Neurology and Metabolism, Hôpital Necker-Enfants Malades, Paris, France.

Shimon Edvardson (S)

Department of Genetics, Hadassah University Hospital, Jerusalem, Israel.

Orli Elpeleg (O)

Department of Genetics, Hadassah University Hospital, Jerusalem, Israel.

Agnès Rötig (A)

Institut Imagine, INSERM UMR 1163, Paris, France.

Arnold Munnich (A)

Department of Genetics, Hospital Necker-Enfants Malades, Paris, France; Institut Imagine, INSERM UMR 1163, Paris, France.

Nathalie Boddaert (N)

Department of Paediatric Radiology, Hôpital Necker-Enfants Malades, Paris, France; Institut Imagine, INSERM UMR 1163, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH